Physician profile
Michael E Loreti
NPI 1851384283
$3,071.62
in general payments reported to CMS, 2019-2025
34 companies · $92.92 in 2025
The $92.92 reported for 2025 was less than what a typical Sports Medicine (Internal Medicine) provider received nationally (typical 2025 total: $99.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $284 · 2021: $517 · 2022: $536 · 2023: $761 · 2024: $382 · 2025: $92.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $467.80 | 2019-2024 | Prolia, Evenity, Enbrel |
| Ucb, INC. | $359.19 | 2020-2025 | Cimzia, Bimzelx |
| Depuy Synthes Sales INC. | $350.56 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $328.04 | 2022-2023 | Seglentis |
| Fidia Pharma USA INC. | $288.00 | 2019-2025 | Hymovis, Triluron |
| Orthofix Medical, INC. | $190.92 | 2023 | Trinity Elite, Physio-Stim |
| Radius Health, INC. | $140.95 | 2019-2025 | Tymlos |
| Stryker Corporation | $128.30 | 2021-2024 | Mako |
| Aurinia Pharma U.S., INC. | $91.73 | 2021-2024 | Lupkynis |
| Alvogen INC | $88.04 | 2024 | Teriparatide |
| Ferring Pharmaceuticals INC. | $66.89 | 2019-2021 | |
| Pfizer INC. | $49.87 | 2020-2021 | |
| Zyla Life Sciences, INC. | $43.06 | 2019-2020 | |
| Si-Bone, INC. | $43.00 | 2020-2021 | |
| Orthogenrx INC. | $34.64 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $29.19 | 2022 | |
| Genzyme Corporation | $28.79 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $28.20 | 2023 | Iovera, Zilretta, Exparel |
| Horizon Therapeutics Plc | $27.97 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.74 | 2022-2023 | Relistor |
| Collegium Pharmaceutical, INC. | $25.71 | 2019 | |
| Integra Lifesciences Corporation | $22.05 | 2020 | |
| Abbott Laboratories | $21.75 | 2021 | |
| Virtus Pharmaceuticals LLC | $20.96 | 2020-2021 | |
| Medacta USA, INC. | $20.31 | 2025 | Spherika |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.91 | 2022 | |
| Boston Scientific Corporation | $19.85 | 2019 | |
| Heraeus Medical, LLC. | $18.67 | 2022 | |
| Zimmer Biomet Holdings, INC. | $16.58 | 2020 | |
| Scilex Pharmaceuticals INC. | $16.54 | 2024 | |
| Alexion Pharmaceuticals, INC. | $14.60 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.40 | 2019 | |
| Sobi, INC | $14.29 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $13.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Loreti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.